Clinical experience with angiogenesis signaling inhibitors: Focus on vascular endothelial growth factor (VEGF) blockers

Cancer Control

Volumn 9, Issue 2 SUPPL., 2002, Pages 36-44

  Rosen, Lee S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTINEOPLASTIC AGENT; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; MONOCLONAL ANTIBODY; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; SEMAXANIB; THALIDOMIDE; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VATALANIB;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; ANIMAL MODEL; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLON CANCER; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TARGETING; GLIOMA CELL; HUMAN; KAPOSI SARCOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RAT; REVIEW; TUMOR GROWTH;

EID: 0036240885     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200902s05     Document Type: Review

References (111)

1. What is the evidence that tumors are angiogenesis dependent?
2. Angiogenic factors
3. Ischemia-driven angiogenesis
4. Tumor angiogenesis: Therapeutic implications
5. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation
6. Vascular endothelial growth factor as a target for antiangiogenic therapy
7. Vascular endothelial growth factor in human glioma cell lines: Induced secretion by EGF, PDGF-BB, and bFGE
8. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I
9. Regulation of vascular endothelial growth factor expression in human colon cancer by interleukin-1beta
10. Interleukin 6 induces the expression of vascular endothelial growth factor
11. Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells
12. Vascular endothelial cell growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
13. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: Implications for tumor angiogenesis
14. Angiogenesis in cancer and other diseases
15. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
16. PGE2 and angiogenesis
17. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
18. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells
19. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
20. Regulation of angiogenesis by controlling VEGF receptor
21. Tumour vasculature as a target for anticancer therapy
22. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryonic neovascularization
23. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
24. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity
25. Vascular endothelial growth factor and its receptors
26. VEGF receptor signaling in tumor angiogenesis
27. The biology of vascular endothelial growth factor
28. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
29. Exogenous vascular endothelial growth factor induces malformed and hyperfused vessels during embryonic neovascularization
30. Tumors: Wounds that do not heal. Similarity between tumor stroma generation and wound healing
31. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor
32. Vascular endothelial growth factor (VEGF) and its receptors
33. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells
34. New paradigms for the treatment of cancer: The role of anti-angiogenesis agents
35. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
36. Clinical implications of circulating angiogenic factors in cancer patients
37. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
38. How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases
39. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma
40. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer
41. Serum VEGF levels in women with a benign breast tumor or breast cancer
42. Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat
43. Correlation of bFGF, FGFR-1 and VEGF expression with vascularity and malignancy of human astrocytomas
44. Vascular endothelial growth factor (VEGF) - A valuable serum tumour marker in patients with colorectal cancer?
45. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma
46. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas
47. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen
48. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer
49. Plasma concentrations of VEGF and bFGF in patients with gastric carcinoma
50. Vascular endothelial growth factor (VEGF) is elevated in brain tumor cysts and correlates with tumor progression
51. Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix
52. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas
53. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer
54. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma
55. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma
56. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
57. Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression
58. Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients
59. Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma
60. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer
61. Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer
62. Increased expression of vascular endothelial growth factor is associated with tumor progression in hepatocellular carcinoma
63. Vascular endothelial growth factor expression in non-small-cell lung cancer: Prognostic significance in squamous cell carcinoma
64. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma
65. Vascular endothelial growth factor expression in early stage ovarian carcinoma
66. Significance of vascular endothelial growth factor messenger RNA expression in primary lung cancer
67. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment
68. p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma
69. Does vascular endothelial growth factor (VEGF) predict local relapse and survival in radiotherapy-treated node-negative breast cancer?
70. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
71. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer
72. Vascular endothelial growth factor A (VEGF-A) mRNA expression levels decrease after menopause in normal breast tissue but not in breast cancer lesions
73. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: Pharmacologic and long-term safety data
74. Importance of VEGF for breast cancer angiogenesis in vivo: Implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin
75. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells
76. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR
77. Inhibition of tumor growth by targeting tumor endothelium using a soluble vascular endothelial growth factor receptor
78. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site
79. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors
80. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent
81. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
82. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy
83. ZD4190: An orally active inhibitor of vascular endothelial growth factor signaling with broadspectrum antitumor efficacy
84. Clinical strategy for the development of angiogenesis inhibitors
85. Tumor angiogenesis: Past, present and the near future
86. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
87. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease
88. Pleural diseases related to metastatic malignancies
89. Targeting vascular endothelial growth factor blockade: Ascites and pleural effusion formation
90. Markedly elevated levels of vascular endothelial growth factor in malignant ascites
91. Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions
92. Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor
93. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas
94. Activity profile of SU5416, a small molecule Flk-1/KDR inhibitor, in tumor xenograft models
95. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy
96. Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastases and induces tumor and endothelial apoptosis
97. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function
98. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies
99. SU5416, a molecularly targeted novel anti-angiogenesis drug: Clinical pharmacokinetics and safety review
100. A multicenter, dose escalating study in patients with AIDS-related Kaposi's sarcoma
101. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors
102. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
103. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
104. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer
105. A phase II trial of single-agent Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer
106. A randomized phase II trial comparing Rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC
107. Role of vascular endothelial growth factor (VEGF) in endothelial cell protection against cytotoxic agents
108. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors